IP Library › Granted Patent US 12,485,171
Granted Patent B2
US 12,485,171 · App. 17/484,786 · Granted Dec 2, 2025

Methods of disease activity profiling for personalized therapy management

Inventors: Sharat Singh (Rancho Santa Fe, CA); Nicholas Hoe (San Diego, CA); Steve Lockton (San Diego, CA); Scott Hauenstein (San Diego, CA); Linda Ohrmund (San Diego, CA)
Assignee: PROMETHEUS LABORATORIES INC.
A61K39/3955C12Q1/6883G01N33/6893C12Q2600/106C12Q2600/156C12Q2600/158G01N2800/065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,485,171
App. No.
17/484,786
Granted
Dec 2, 2025
Kind
B2
Abstract

The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

Claims (24)

1 . A method of treating Ulcerative Colitis (UC) in a subject, the method comprising: administering a therapeutically effective amount of a therapeutic agent to the subject to treat the UC, based, at least partially, on a Mucosal Healing Index (MHI) score of the subject calculated by applying a statistical algorithm to levels of mucosal healing markers measured in a sample obtained from the subject to generate a MHI, and comparing the MHI to an endoscopic score, wherein the therapeutic agent comprises a TNFα inhibitor therapy, an immunosuppressive agent, a corticosteroid, an IL-6 receptor inhibiting antibody, an anti-integrin molecule, a JAK-2 inhibitor, a tyrosine kinase inhibitor, nutrition therapy, or combinations thereof.

2 . The method of claim 1 , wherein the TNFα inhibitor therapy comprises an anti-TNFα antibody.

3 . The method of claim 2 , wherein the anti-TNFα antibody comprises REMICADE™ (infliximab), ENBREL™ (etanercept), HUMIRA™ (adalimumab), CIMZIA® (certolizumab pegol), or any combination thereof.

4 . The method of claim 1 , wherein the immunosuppressive agent comprises azathioprine, 6-mercaptopurine, methotrexate, or any combination thereof.

5 . The method of claim 1 , wherein the nutrition therapy comprises a special carbohydrate diet.

6 . The method of claim 1 , wherein the mucosal healing markers are measured in a sample selected from the group consisting of serum, plasma, whole blood, stool, peripheral blood mononuclear cells (PBMC), polymorphonuclear (PMN) cells, and a tissue biopsy.

7 . The method of claim 1 , wherein the mucosal healing markers comprise AREG, EREG, HB-EGF, HGF, NRG1, NRG2, NRG3, NRG4, BTC, EGF, IGF, TGF-α, VEGF-A, VEGF-B, VEGF-C, VEGF-D, FGF1, FGF2, FGF7, FGF9, TWEAK or combinations thereof.

8 . The method of claim 1 , wherein the mucosal healing markers comprise an anti-TNFα antibody, an anti-drug antibody (ADA), an inflammatory marker, an anti-inflammatory marker, or combinations thereof.

9 . The method of claim 8 , wherein the anti-TNFα antibody comprises REMICADE™ (infliximab), ENBREL™ (etanercept), HUMIRA™ (adalimumab), CIMZIA® (certolizumab pegol), or any combination thereof.

10 . The method of claim 8 , wherein the anti-drug antibody (ADA) comprises a human anti-chimeric antibody (HACA), a human anti-humanized antibody (HAHA), a human anti-mouse antibody (HAMA), or any combination thereof.

11 . The method of claim 8 , wherein the inflammatory marker comprises GM-CSF, IFN-γ, IL-1B, IL-2, IL-6, IL-8, TNF-α, sTNF RII, or any combination thereof.

12 . The method of claim 8 , wherein the anti-inflammatory marker comprises IL-12p70, IL-10, or any combination thereof.

13 . The method of claim 1 , wherein:

(i) the mucosal healing markers comprise GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-8, TNF-α, soluble tumor necrosis factor-α receptor II (sTNF RII), TNF-related weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), IFN-α, IFN-β, IL-1α, IL-1 receptor antagonist (IL-1ra), IL-4, IL-5, soluble IL-6 receptor (sIL-6R), IL-7, IL-9, IL-12, IL-13, IL-15, IL-17, IL-23, IL-27, or any combination thereof;

(ii) the mucosal healing markers comprise MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, MT1-MMP-1, or any combination thereof; or

(iii) the mucosal healing markers comprise C-reactive protein (CRP), D-dimer protein, mannose-binding protein, alpha 1-antitrypsin, alpha 1-antichymotrypsin, alpha 2-macroglobulin, fibrinogen, prothrombin, factor VIII, von Willebrand factor, plasminogen, complement factors, ferritin, serum amyloid P component, serum amyloid A (SAA), orosomucoid (alpha 1-acid glycoprotein (AGP)), ceruloplasmin, haptoglobin, or any combination thereof;

(iv) the mucosal healing markers comprise TGF-α, TGF-β, TGF-2, TGF-β3, or any combination thereof; or

(v) the mucosal healing markers comprise AREG, EREG, HB-EGF, HGF, HRG, NRG1, NRG2, NRG3, NRG4, BTC, EGF, IGF-1, TGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, FGF1, FGF2, FGF7, FGF9, TWEAK, or any combination thereof; or

(vi) the mucosal healing markers comprise IL-10, SCF, ICAM, VCAM, IL-12p40, VEGFA, or any combination thereof.

14 . The method of claim 9 , wherein the mucosal healing markers comprise C-reactive protein (CRP), IL 7, MMP 1, MMP 2, MMP 3, MMP 9, serum amyloid A (SAA), TGFα, VCAM, or any combination thereof.

15 . The method of claim 1 , wherein the subject has rheumatoid arthritis.

16 . The method of claim 1 , further comprising calculating a second MHI score for the subject following the administration of the therapeutically effective amount of the therapeutic agent to the subject to treat the UC.

17 . The method of claim 1 , further comprising administering the therapeutically effective amount of the therapeutic agent to the subject again.

18 . The method of claim 1 , further comprising predicting whether the subject will respond to the TNFα inhibitor therapy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: SINGH, SHARAT; HOE, NICHOLAS; LOCKTON, STEVE; HAUENSTEIN, SCOTT; OHRMUND, LINDA
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 063536/0001 →
Continuity (9)
Continuation 16112242 · Aug 24, 2018
Continuation 14072746 · Nov 5, 2013
Continuation PCTUS2012037375 · May 10, 2012
Provisional Application 61636575 · Apr 20, 2012
Provisional Application 61566509 · Dec 2, 2011
Provisional Application 61553909 · Oct 31, 2011
Provisional Application 61505026 · Jul 6, 2011
Provisional Application 61484607 · May 10, 2011
Related Publication 20220096629A1 · Mar 31, 2022
References Cited (125)
US 5674754A · Ahrens et al. · 1997 [cited by applicant]
US 6319899B1 · Schwartz · 2001 [cited by applicant]
US 7252971B2 · Benson et al. · 2007 [cited by applicant]
US 7932372B2 · Pullen et al. · 2011 [cited by applicant]
US 8012698B2 · Stephens et al. · 2011 [cited by applicant]
US 8165819B2 · Clermont et al. · 2012 [cited by applicant]
US 8293489B2 · Henkin · 2012 [cited by applicant]
US 8538774B2 · Michelson et al. · 2013 [cited by applicant]
US 8630810B2 · Clermont et al. · 2014 [cited by applicant]
US 9732385B2 · Barken et al. · 2017 [cited by applicant]
US 10086072B2 · Singh et al. · 2018 [cited by applicant]
US 11162943B2 · Jain et al. · 2021 [cited by applicant]
US 20020025553A1 · Wei · 2002 [cited by applicant]
US 20030087285A1 · Chow et al. · 2003 [cited by applicant]
US 20040197304A1 · Chen et al. · 2004 [cited by applicant]
US 20050154536A1 · Chow et al. · 2005 [cited by applicant]
US 20060216239A1 · Zhang et al. · 2006 [cited by applicant]
US 20080086272A1 · Fillet · 2008 [cited by applicant]
US 20080162101A1 · Sarna et al. · 2008 [cited by applicant]
US 20080228456A1 · Clermont et al. · 2008 [cited by applicant]
US 20090156418A1 · Blank et al. · 2009 [cited by applicant]
US 20100255513A1 · Denson et al. · 2010 [cited by applicant]
US 20110045476A1 · Barken et al. · 2011 [cited by applicant]
US 20110059445A1 · Rutgeerts et al. · 2011 [cited by applicant]
US 20120046197A1 · Glezer et al. · 2012 [cited by applicant]
US 20130071860A1 · Hale et al. · 2013 [cited by applicant]
US 20130224210A1 · Adamkewicz et al. · 2013 [cited by applicant]
US 20130273566A1 · Denson et al. · 2013 [cited by applicant]
US 20140113306A1 · Haimovich et al. · 2014 [cited by applicant]
US 20140141983A1 · Singh et al. · 2014 [cited by applicant]
US 20140236166A1 · Park et al. · 2014 [cited by applicant]
US 20140329721A1 · Joern et al. · 2014 [cited by applicant]
US 20140356882A1 · Moses et al. · 2014 [cited by applicant]
US 20150072879A1 · Princen et al. · 2015 [cited by applicant]
US 20150301055A1 · Spetzler · 2015 [cited by applicant]
US 20150355195A1 · Singh et al. · 2015 [cited by applicant]
US 20170360926A1 · Rosario et al. · 2017 [cited by applicant]
US 20170368027A1 · Blum-Sperisen et al. · 2017 [cited by applicant]
US 20180086833A1 · Hassanali et al. · 2018 [cited by applicant]
US 20190060449A1 · Singh et al. · 2019 [cited by applicant]
US 20220082563A1 · Jain · 2022 [cited by applicant]
CA 2772916A1 · 2011 [cited by applicant]
CN 1764838A · 2006 [cited by applicant]
CN 1839157A · 2006 [cited by applicant]
CN 101291693A · 2008 [cited by applicant]
CN 101472611A · 2009 [cited by applicant]
EP 1725876B1 · 2009 [cited by applicant]
JP 2006521537A · 2006 [cited by applicant]
RU 2141332C1 · 1999 [cited by applicant]
WO WO2004090539A2 · 2004 [cited by applicant]
WO WO2005000897A2 · 2005 [cited by applicant]
WO WO2005009339A2 · 2005 [cited by applicant]
WO WO2007050607A2 · 2007 [cited by applicant]
WO WO2007149814A1 · 2007 [cited by applicant]
WO WO2008036802A2 · 2008 [cited by applicant]
WO WO2009012140A2 · 2009 [cited by applicant]
WO WO2009108637A1 · 2009 [cited by applicant]
WO WO2010025340A2 · 2010 [cited by applicant]
WO WO2010132723A1 · 2010 [cited by applicant]
WO WO2010151699A1 · 2010 [cited by applicant]
WO WO2011008990A1 · 2011 [cited by applicant]
WO WO2011050069A1 · 2011 [cited by applicant]
WO WO2011066458A2 · 2011 [cited by applicant]
WO WO2011153501A2 · 2011 [cited by applicant]
WO WO2012088337A1 · 2012 [cited by applicant]
WO WO2012119113A2 · 2012 [cited by applicant]
WO WO2012154987A1 · 2012 [cited by applicant]
WO WO2013033623A1 · 2013 [cited by applicant]
WO WO2014054013A1 · 2014 [cited by applicant]
WO WO2015110989A1 · 2015 [cited by applicant]
WO WO2018220588A1 · 2018 [cited by applicant]
WO WO2020117795A1 · 2020 [cited by applicant]
Algaba et al.: Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-hase reactants in patients with inflammatory bowel disease. J Crohns… [cited by applicant]
Baugh et al.: Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 117:814-822 (1999). [cited by applicant]
Breiman et al.: Chapter 6 Medical diagnosis and prognosis. Classification and regression trees. Chappman & Hall/CRC (1984) (pp. 174-346). [cited by applicant]
BREIMAN: Random Forests. Machine Learning, 45; 5-32 (2001) http://stat-www.berkeley.edu/users/breiman/RandomForests/cc_home.htm. [cited by applicant]
Carman et al.: Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn's disease. Gastrointest Endosc. 89(2):364-372 (2019). [cited by applicant]
Chambers et al.: Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. European Journal of Clinical Investigation. 1… [cited by applicant]
Christensen et al.: Understanding endoscopic disease activity in IBD: how to incorporate it into practice. Curr Gastroenterol Rep. 18(1):5 (2016). [cited by applicant]
Daperno et al.: Results of the 2nd part scientific workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. Journal of Crohn's and C… [cited by applicant]
Daperno et al.: Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointestinal Endoscopy. 60(4):505-512 (2004). [cited by applicant]
Dave et al.: Mucosal healing in inflammatory bowel disease—A true paradigm of success?. Gastroenterology & Hepatology. 8(1):29-38 (2012). [cited by applicant]
De Bruyn et al.: Biomarker Panel for Prediction of Mucosal Healing in Patients With Crohn's Disease Under Infliximab Therapy. Biosciences Information Service (2014). [cited by applicant]
D'Haens et al.: Development and Validation of a Test to Monitor Endoscopic Activity in Patients with Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology. vol. Pii:S0016-5085(19)41525-4 (2019). [cited by applicant]
Disabatino et al.: Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab. European Journal of Gastroenterology and Hepatology. 21(9):1049-55… [cited by applicant]
Efsen et al.: Ramiprilate Inhibits Functional Matrix Metalloproteinase Activity in Crohn's Disease Fistulas. Basic and Clinical Pharmacy and Toxicology. 109(3):208-216 (2011). [cited by applicant]
Epstein et al.: Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1b and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. … [cited by applicant]
Ferrante et al.: Validation of Endoscopic Activity Scores in Patients with Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC. Gastroenterology. 145(5):978-986 (2013). [cited by applicant]
Freeman et al.: Neural Networks: Algorithms, Applications and Programming Techniques. Addison-Wesley Publishing Company; 414 pages (1991). [cited by applicant]
Froslie et al.: Mucosal healing in inflammatory bowel disease: Results from a Norwegian populaiton-based cohort. Gastroenterology. 133:412-422 (2007). [cited by applicant]
Geboes et al.: Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinio… [cited by applicant]
Ghosh et al.: Anti-TNF therapy in Crohn's disease Novartis Foundation Symposium 263:193-218 (2004). [cited by applicant]
Gordon et al.: CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. Journal of Crohn's and Colitis. 175-182 (2009). [cited by applicant]
Hu et al.: Research Progress of Inflammatory Bowel Disease. Basic and Clinical Medicine, Guangdong Science & Technology Press, Ltd.; pp. 46-47 (2006) machine translation. [cited by applicant]
International Application No. PCT/IB2013/059077 International Preliminary Report on Patentability dated Apr. 7, 2015. [cited by applicant]
International Application No. PCT/IB2013/059077 International Search Report and Written Opinion dated Dec. 5, 2013. [cited by applicant]
International Application No. PCT/IB2018/053923 International Search Report and Written Opinion dated Jul. 27, 2018. [cited by applicant]
International Application No. PCT/US2012/037375 International Search Report and Written Opinion dated Aug. 16, 2012. [cited by applicant]
Jiang et al.: Study on anti-tumor necrosis factor antibody for the treatment of inflammatory bowel disease. Clinical Medication Journal. 9(2):16-20 (2011). [cited by applicant]
Kelly et al.: Development and validation of a multi-marker serum test for the assessment of mucosal healing in Crohn's disease patients. American College of Gastroenterology. (2017). [cited by applicant]
Lewis: The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 140:1817-1826 (2011). [cited by applicant]
Li et al.: The effect of hepatocyte growth factor (Hgf) on mucosal morphology and absorption after rat small intestine transplantation. Medical Journal of Chinese People's Liberation Army. 25(4):242-244 (2000). [cited by applicant]
Moskovitz et al.: Defining and validating cut-offs for the Simple Endoscopic Score for Crohn's Disease. Gastroenterology. 132:S1097 (2007). [cited by applicant]
Neurath et al.: Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 61:1619-1635 (2012). [cited by applicant]
Noble et al.: Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut. 57:1398-1405 (2008). [cited by applicant]
Oliva et al.: Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroentero… [cited by applicant]
Ouyang: Editor-in-chief, Research Advances in Inflammatory Bowel Disease. Chengdu: Sichuan Science and Technology Press. pp. 207-210 (2000). [cited by applicant]
PCT/IB2013/059077 International Search Report and Written Opinion dated Dec. 5, 2013. [cited by applicant]
PCT/US2019/064224 International Preliminary Report on Patentability dated Jun. 17, 2021. [cited by applicant]
PCT/US2019/064224 International Search Report and Written Opinion dated Feb. 12, 2020. [cited by applicant]
Peyrin-Biroulet et al.: Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 110(9):1324-1338 (2015). [cited by applicant]
Prometheus® Monitr™ Crohn's Disease Cat. #7300. Prometheus® Therapeutics & Diagnostics website (2018). [cited by applicant]
Scaldaferri et al.: Mucosal biomarkers in inflammatory bowel disease: Key pathogenic players or disease predictors?. World Journal of Gastroenterology. 16(21):2616-2625 (2010). [cited by applicant]
Schoepfer et al.: Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. Journal of Crohn's and Colitis. 6:412-418 (2012). [cited by applicant]
Sipponen et al.: Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 16:2131-2136 (2010). [cited by applicant]
Steinberg et al.: CART: Tree Structured Non-Parametric Data Analysis. Salford Systems. 355 pages (1995). [cited by applicant]
Toedter et al.: Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease. American Journal of Gastroenterology. 104(11):2768-2773 (2009). [cited by applicant]
Tutina et al.: Lechebnoe pitanie pri nespetsificheskom yazvennom kolite i bolezni Krona u detei [Nutritional therapy for nonspecific ulcerative colitis and Crohn's disease in children]. Pediatricheskaya farmakologiya. 5… [cited by applicant]
U.S. Appl. No. 16/112,242 Final Office Action dated Apr. 14, 2021. [cited by applicant]
U.S. Appl. No. 16/112,242 Office Action dated Sep. 3, 2020. [cited by applicant]
U.S. Appl. No. 16/614,752 Final Office Action dated Sep. 22, 2020. [cited by applicant]
U.S. Appl. No. 16/614,752 Office Action dated Apr. 9, 2021. [cited by applicant]
U.S. Appl. No. 16/614,752 Office Action dated Jun. 11, 2020. [cited by applicant]
Vuitton et al.: IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 65(9):1447-1455 (2016). [cited by applicant]
Zadeh: Fuzzy Sets. Information and Control; 8:338-353 (1965). [cited by applicant]